Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Alnylam Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2002-01-01

Employees: -

Market Cap: $35.9B

Website: http://www.alnylam.com/

Clinical Trials

APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis

Phase 3

Completed

Conditions: TTR-mediated Amyloidosis
Amyloid Neuropathies, Familial
Amyloid Neuropathies
Amyloidosis, Hereditary
Familial Amyloid Polyneuropathies
Amyloidosis, Hereditary, Transthyretin-Related

Interventions: Drug: patisiran (ALN-TTR02)
Drug: Sterile Normal Saline (0.9% NaCl)

First Posted Date: 2013-10-10

Last Posted Date: 2024-04-22

Lead Sponsor: Alnylam Pharmaceuticals

Target Recruit Count: 225

Registration Number: NCT01960348

Locations: 🇬🇧
Clinical Trial Site, London, United Kingdom

A Phase 1, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-TTRSC (Revusiran) in Healthy Volunteers

Phase 1

Completed

Conditions: TTR-mediated Amyloidosis

Interventions: Drug: ALN-TTRSC (revusiran)
Drug: Sterile Normal Saline (0.9% NaCl)

First Posted Date: 2013-03-20

Last Posted Date: 2016-02-05

Lead Sponsor: Alnylam Pharmaceuticals

Target Recruit Count: 85

Registration Number: NCT01814839

Locations: 🇬🇧
Clinical Site, London, United Kingdom

Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis

Phase 2

Completed

Conditions: TTR-mediated Amyloidosis

Interventions: Drug: Patisiran

First Posted Date: 2012-06-13

Last Posted Date: 2024-04-19

Lead Sponsor: Alnylam Pharmaceuticals

Target Recruit Count: 29

Registration Number: NCT01617967

Locations: 🇸🇪
Clinical Trial Site, Umeå, Sweden

Trial to Evaluate Safety, Tolerability, and Parmacokinetics of ALN-TTR02 in Healthy Volunteer Subjects

Phase 1

Completed

Conditions: TTR-mediated Amyloidosis

Interventions: Drug: ALN-TTR02
Drug: Sterile Normal Saline (0.9% NaCl)

First Posted Date: 2012-03-21

Last Posted Date: 2013-01-15

Lead Sponsor: Alnylam Pharmaceuticals

Target Recruit Count: 17

Registration Number: NCT01559077

Locations: 🇬🇧
Clinical Site, London, United Kingdom

Trial to Evaluate Safety and Tolerability of ALN-PCS02 in Subjects With Elevated LDL-Cholesterol (LDL-C)

Phase 1

Completed

Conditions: Elevated LDL-Cholesterol (LDL-C)

Interventions: Drug: ALN-PCS02
Drug: Sterile Normal Saline (0.9% NaCl)

First Posted Date: 2011-09-20

Last Posted Date: 2012-10-12

Lead Sponsor: Alnylam Pharmaceuticals

Target Recruit Count: 32

Registration Number: NCT01437059

Locations: 🇬🇧
Clinical Site, London, United Kingdom

Multi-center, Open Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 Treatment

Phase 1

Completed

Conditions: Solid Tumors

First Posted Date: 2010-07-08

Last Posted Date: 2012-10-12

Lead Sponsor: Alnylam Pharmaceuticals

Target Recruit Count: 7

Registration Number: NCT01158079

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇪🇸
Hospital Virgen del Rocio, Seville, Andalucia, Spain

and more 7 locations

Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) Amyloidosis

Phase 1

Completed

Conditions: Transthyretin Mediated Amyloidosis (ATTR)

Interventions: Drug: ALN-TTR01
Drug: Sterile Normal Saline (0.9% NaCl)

First Posted Date: 2010-06-23

Last Posted Date: 2012-05-24

Lead Sponsor: Alnylam Pharmaceuticals

Target Recruit Count: 32

Registration Number: NCT01148953

Locations: 🇬🇧
Clinical Site, London, United Kingdom

Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)

Phase 2

Completed

Conditions: Respiratory Syncytial Virus Infections

Interventions: Drug: Normal Saline
Drug: ALN-RSV01

First Posted Date: 2010-02-10

Last Posted Date: 2018-02-05

Lead Sponsor: Alnylam Pharmaceuticals

Target Recruit Count: 87

Registration Number: NCT01065935

Locations: 🇩🇪
Clinical Site, Leipzig, Germany

Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 In Patients With Advanced Solid Tumors With Liver Involvement

Phase 1

Completed

Conditions: Solid Tumors

First Posted Date: 2009-04-16

Last Posted Date: 2011-08-24

Lead Sponsor: Alnylam Pharmaceuticals

Target Recruit Count: 41

Registration Number: NCT00882180

Locations: 🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 7 locations

Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)

Phase 2

Completed

Conditions: Respiratory Syncytial Virus Infections

Interventions: Drug: normal saline
Drug: ALN-RSV01

First Posted Date: 2008-04-14

Last Posted Date: 2018-01-29

Lead Sponsor: Alnylam Pharmaceuticals

Target Recruit Count: 24

Registration Number: NCT00658086

Locations: 🇦🇺
Clinical Site, Perth, Western Australia, Australia

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy